IDSA members can support IDSA’s goal of having 10 new antibiotics by 2020 by taking three minutes to sign the latest Action Alert urging the Senate to pass the recently reintroduced PATH Act. PATH, or Promise for Antibiotics and Therapeutics for Health, would establish a new limited population antibacterial drug approval pathway for antibacterial drugs to treat serious or life-threatening infections where there exists an unmet medical need. This important legislation was recently reintroduced in the Senate by Sens. Orrin Hatch (R-UT) and Michael Bennet (D-CO).More good news on the antibiotic front was announced late last year with the approval of ceftolozane/tazobactam from Cubist Pharmaceuticals. This is the fifth antibiotic approved since the launch of the 10 x ’20 initiative in 2010.
Although IDSA applauded the new drug’s approval, the Society’s press statement pointed out that patients still face life-threatening infections for which additional new antibiotics are urgently needed. The PATH Act would help by reducing regulatory burdens to new drug development.
< Previous Article | Next Article >